Amendment to Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

On March 26, 2012, the Office of Administrative Law approved amendments to Title 27, California Code of Regulations, section 25705(b)(1), that adopt 11 micrograms per day as the No Significant Risk Level for imazalil for purposes of Proposition 65.  The amendment is effective on April 25, 2012.

Questions regarding this regulatory action can be directed to Monet Vela, at monet.vela@oehha.ca.gov or (916) 323-2517 or Fran Kammerer, Staff Counsel at fran.kammerer@oehha.ca.gov or (916) 445-4396.

Comment Period

• Comment Period - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil
• Extension of Comment Period - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

Downloads

Final Statement of Reasons -Title 27 Section 25705 No Significant Risk Levels for Imazalil
Apr 25, 2012

Final Regulatory Text -Title 27 Section 25705 No Significant Risk Levels for Imazalil
Apr 25, 2012

Chemical Reference

• Imazalil

Meeting Announcements/Information

• Hearing - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

Related Notices

• Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

  Sep 23, 2011
• Notice of Withdrawal and Resubmittal of Proposed Rulemaking Amendment to Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

  Sep 23, 2011